Investigating EGR1 signaling pathways in aggressive lymphoma
Targeting EGR1 signaling pathways in diffuse large B cell lymphoma
This study is looking at a tough type of lymphoma called ABC DLBCL to figure out why some treatments don’t work and hopes to find new ways to help patients who haven’t had success with current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-10982513 on NIH RePORTER |
What this research studies
This research focuses on diffuse large B cell lymphoma (DLBCL), particularly the activated B cell-like (ABC) subtype, which is known for its aggressive nature and poor response to current treatments. The study aims to understand the mechanisms behind drug resistance in ABC DLBCL, especially in relation to the EGR1 protein, which plays a crucial role in the survival and proliferation of these cancer cells. By targeting EGR1 and its associated signaling pathways, the research seeks to develop new therapeutic strategies that could improve treatment outcomes for patients who have not responded to existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with activated B cell-like diffuse large B cell lymphoma who have experienced treatment resistance.
Not a fit: Patients with other types of lymphoma or those who have not been diagnosed with diffuse large B cell lymphoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with aggressive forms of lymphoma, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results in targeting similar signaling pathways in other cancers, suggesting potential for success in this novel approach.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Rui, Lixin — University of Wisconsin-Madison
- Study coordinator: Rui, Lixin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.